Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2022-08-05

FDA Approved: MYFEMBREE — Supplemental Application (Sumitomo Pharma America, Inc)

View source ↗

Summary

FDA approved a supplemental application for MYFEMBREE (relugolix, estradiol hemihydrate, and norethindrone acetate) from Sumitomo Pharma America, updating the p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MYFEMBREE (relugolix, estradiol hemihydrate, and norethindrone acetate)

Snippet

SUPPL AP for MYFEMBREE (RELUGOLIX, ESTRADIOL HEMIHYDRATE, AND NORETHINDRONE ACETATE)